Keyphrases
Adverse Pregnancy Outcomes
5%
African Women
6%
Antiretroviral Therapy
20%
Antiviral Drugs
11%
Apologizing
5%
Baseline Analysis
5%
Bone Mineral Density
5%
Breast Milk
5%
Breastfeeding Mothers
5%
Breastfeeding Women
8%
Confidence Interval
19%
Effects on Growth
5%
Emtricitabine
5%
Emtricitabine Triphosphate
5%
Exposed Uninfected
5%
HIV Patients
17%
HIV Prevention
5%
HIV Transmission
13%
HIV-1 Infection
5%
HIV-exposed
5%
Human Immunodeficiency Virus Type 1 (HIV-1)
5%
Implementation Barriers
5%
Infant Survival
5%
Liver Fibrosis
5%
Long-term Antiretroviral Therapy
5%
Malawi
9%
Male Circumcision
5%
Maternal Antiretroviral Therapy
7%
Maternal Survival
5%
Multi-country Study
7%
Neurodevelopmental Outcome
5%
Nevirapine
7%
Nevirapine Prophylaxis
5%
Observational Cohort Study
5%
Operational Barriers
5%
Operational Issues
5%
People Living with HIV (PLHIV)
16%
PEPFAR
10%
PMTCT
13%
Pregnant Women
6%
Progressive Liver Fibrosis
5%
PROMISE Study
5%
Randomized Clinical Trial
5%
Randomized Trial
5%
Serum Biomarkers
5%
South Africa
5%
Southern Africa
5%
Sub-Saharan Africa
10%
Uganda
29%
Women of Reproductive Age
5%
Medicine and Dentistry
Antiretroviral Therapy
36%
Arm
12%
Awareness
5%
Biological Marker
5%
Bone Density
5%
Childbirth
11%
Clinical Research
5%
Cohort Effect
5%
Cohort Study
5%
Contraceptive Behavior
5%
Cross Sectional Study
7%
Graduate Student
5%
Hazard Ratio
5%
Health Promotion
5%
Hepatitis B
10%
Hepatitis B Virus
10%
Hepatocellular Carcinoma
5%
Human Immunodeficiency Virus
100%
Human Immunodeficiency Virus 1 Infection
5%
Human Immunodeficiency Virus Infection
10%
Human Milk
5%
Infant Survival
6%
Liver Fibrosis
10%
Maternal Plasma
5%
Neonatal Infant
10%
Nevirapine
22%
Placebo
5%
Prevalence
12%
Prospective Cohort Study
5%
Randomized Clinical Trial
7%
Single Drug Dose
5%
Tenofovir
10%
Tenofovir/Emtricitabine
5%
Viral Clearance
5%
Viremia
5%
Nursing and Health Professions
Antiretroviral Therapy
12%
Circumcision
5%
Confidence Interval
10%
Graduate Student
5%
Health Practitioner
5%
Health Services Research
5%
Hepatitis B
5%
Hospital
5%
Human Immunodeficiency Virus
41%
Human Immunodeficiency Virus 1 Infection
5%
Human Immunodeficiency Virus Infection
8%
Infection
5%
Liver Cell Carcinoma
5%
Liver Fibrosis
5%
Nevirapine
10%
Pilot Study
5%
Placebo
5%
Practice Guideline
5%
Prevalence
8%
Rural Health Care
5%
Severe Acute Respiratory Syndrome
5%
Transvaginal Sling
5%
Virus Load
6%
